Figure 7.
Effects of S100A8 on MSC proliferation and differentiation. (A) Representative plots of CFU-F for the S100A8 overexpression group and control group. (B) CFU-F counts in the S100A8 overexpression group and control group (n = 3). (C) The proliferation of MSCs in the S100A8 overexpression and control groups (n = 4). (D) Cell cycle status of MSCs in the S100A8 overexpression and control groups (n = 3). (E) MSC apoptosis in the S100A8 overexpression and control groups (n = 3). (F) Flow diagram of BM MSCs of S100A8-deficient and control mice. (G-I) MSC ratio in BM of S100A8-deficient and control mice after 5-FU treatment (G), IR exposure (H), and AML (I; n = 5-7). (J) Representative images of Alizarin red staining (osteogenic differentiation) of MSC in the S100A8 overexpression and control groups. (K-L) quantitative reverse transcription polymerase chain reaction analysis of osteoblastic differentiation relative genes (OPN and OCN) in MSCs from the S100A8 overexpression group and control group (n = 3). (M) A flow diagram of BM OBCs from S100A8-deficient and control mice. (N-O) OBC ratio in the BM of S100A8-deficient and control mice after 5-FU treatment (N) and IR exposure (O; n = 5-6). (P-R) Microcomputed tomography analysis of the trabecular bone in S100A8-deficient and control AML mice. Representative images are displayed in panel P (scale bars, 1 mm). (Q-R) Trabecular BT/BV and Tb. N in the femoral metaphysis are illustrated (n = 4). (S) Enzyme-linked immunosorbent assay analysis of BM protein concentrations of OPN in S100A8-deficient and control AML mice (n = 5). ∗P < .05; ∗∗P < .01; ∗∗∗P < .001. BT/BV, bone volume/total volume; Ctrl, control; KO, knockout; Tb. N, trabecular number.

Effects of S100A8 on MSC proliferation and differentiation. (A) Representative plots of CFU-F for the S100A8 overexpression group and control group. (B) CFU-F counts in the S100A8 overexpression group and control group (n = 3). (C) The proliferation of MSCs in the S100A8 overexpression and control groups (n = 4). (D) Cell cycle status of MSCs in the S100A8 overexpression and control groups (n = 3). (E) MSC apoptosis in the S100A8 overexpression and control groups (n = 3). (F) Flow diagram of BM MSCs of S100A8-deficient and control mice. (G-I) MSC ratio in BM of S100A8-deficient and control mice after 5-FU treatment (G), IR exposure (H), and AML (I; n = 5-7). (J) Representative images of Alizarin red staining (osteogenic differentiation) of MSC in the S100A8 overexpression and control groups. (K-L) quantitative reverse transcription polymerase chain reaction analysis of osteoblastic differentiation relative genes (OPN and OCN) in MSCs from the S100A8 overexpression group and control group (n = 3). (M) A flow diagram of BM OBCs from S100A8-deficient and control mice. (N-O) OBC ratio in the BM of S100A8-deficient and control mice after 5-FU treatment (N) and IR exposure (O; n = 5-6). (P-R) Microcomputed tomography analysis of the trabecular bone in S100A8-deficient and control AML mice. Representative images are displayed in panel P (scale bars, 1 mm). (Q-R) Trabecular BT/BV and Tb. N in the femoral metaphysis are illustrated (n = 4). (S) Enzyme-linked immunosorbent assay analysis of BM protein concentrations of OPN in S100A8-deficient and control AML mice (n = 5). ∗P < .05; ∗∗P < .01; ∗∗∗P < .001. BT/BV, bone volume/total volume; Ctrl, control; KO, knockout; Tb. N, trabecular number.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal